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Bacteriocins are toxins produced by bacteria to kill competitors of the same
species. Theory and laboratory experiments suggest that bacteriocin pro-
duction and immunity play a key role in the competitive dynamics of
bacterial strains. The extent to which this is the case in natural populations,
especially human pathogens, remains to be tested. We examined the role of
bacteriocins in competition using Pseudomonas aeruginosa strains infecting
lungs of humans with cystic fibrosis (CF). We assessed the ability of different
strains to kill each other using phenotypic assays, and sequenced their gen-
omes to determine what bacteriocins (pyocins) they carry. We found that
(i) isolates from later infection stages inhibited earlier infecting strains less,
but were more inhibited by pyocins produced by earlier infecting strains
and carried fewer pyocin types; (ii) this difference between early and late infec-
tions appears to be caused by a difference in pyocin diversity between
competing genotypes and not by loss of pyocin genes within a lineage over
time; (iii) pyocin inhibition does not explain why certain strains outcompete
others within lung infections; (iv) strains frequently carry the pyocin-killing
gene, but not the immunity gene, suggesting resistance occurs via other
unknownmechanisms. Our results show that, in contrast to patterns observed
in experimental studies, pyocin production does not appear to have a major
influence on strain competition during CF lung infections.
1. Introduction
Bacteria produce antimicrobial toxins, termed bacteriocins, to kill competitors [1]. A
number of experimental studies have shown that bacteriocins can play a key role in
competitive dynamics among closely related bacterial strains [2,3]. Bacteriocin ‘pro-
ducers’ can invade and outcompete ‘sensitive’ strains that are killed by that toxin.
These producers can, in turn, be outcompeted by ‘resistant’ strains that are immune
to the bacteriocin, but do not produce it, and hence do not pay themetabolic cost of
producing it. While the ‘resistant’ strains can be outcompeted by ‘sensitive’ strains
because sensitive strains donot invest in themetabolic production of expressing the
immunity protein that neutralizes the toxin. In spatially structured populations this
can lead to population dynamic cycling with all three strains coexisting, analogous
to the rock–paper–scissors (RPS) game, because each strain can be invaded by
another strain—producers outcompete sensitive, resistant outcompete producers
and sensitive outcompete resistant [1,4,5].
The extent to which bacteriocins determine the dynamics of competing
Pseudomonas aeruginosa strains in nature, or lead to RPS dynamics, is not
known. In addition, previous work has focused on Escherichia coli, which carry
bacteriocins with relatively simple toxin–antitoxin systems, where one protein
is responsible for the killing action (toxin) and another immunity protein for neu-
tralizing the killing protein [4,6]. However, in natural populations of bacteria like
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P. aeruginosa one strain usually carries and releases multiple
types of bacteriocins known as pyocins, which have a diversity
of killing and resistance mechanisms in addition to the toxin–
antitoxin systems [2,7]. For example, three pyocin types exist (S,
R and F), with each of these having multiple subtypes with
varying toxicity levels [2,7–10]. The soluble S-type is similar
to colicins of E. coli and is composed of killing and immunity
genes. While the R and F type are phage-derived and have
different killing and resistancemechanisms,where both consist
of only a killing component with no specified immunity that
neutralizes the toxin but instead resist via alteration or absence
of cell-surface receptors [2,9–15].
We examine bacteriocin-mediated population dynamics
in natural populations using cystic fibrosis (CF) lung isolates
of P. aeruginosa, an opportunistic human pathogen. Early
colonization of the lung is characterized by a diversity of strains
that intermittently co-infect from environmental sources or other
patients, while later stages are characterized by chronic infec-
tions usually dominated by one strain [13,16–19]. Our first
aim was to test whether the competitive success of different
strains, within hosts, can be explained by variation in pyocin
production and resistance. In particular, whether the production
of bacteriocins has allowed certain strains to eliminate competi-
tors and become dominant. We examined the extent to which
different strains where able to produce pyocins that inhibited
the growth of other strains, comparing: (i) isolates sampled
from non-lung environments and 13 CF Danish patients at
different stages of infection and (ii) isolates sampled from a
longitudinal study following the infection dynamics of strains
within eight CF Danish patients. We sequenced the genomes
of all these strains to identify the pyocin genes, examine how
pyocin diversity changes during lung infections and examine
the genetic basis of the inhibition patterns that we observed phe-
notypically.We tested the generality of our results by comparing
our sequence data with that from previously sequenced epi-
demic strains, and from 55 isolates of a transmissible Danish
isolate that has been sampled for over 38 years [20].
Our second aimwas to test whether RPS dynamics occur in
natural P. aeruginosa populations. We used all the isolates
to assess the frequency of occurrence of the different types
of producer, resistant and sensitive strains. Theory predicts
that structured populations allow all these types to be main-
tained at appreciable frequencies, whereas sensitives will
dominate in unstructured (panmictic) populations [4,21–23].
We do not know the extent to which human hosts represent
relatively structured or unstructured populations. We focus
on S pyocins because they are composed of a killing and
immunity gene, and in particular, the five S pyocin types
for which both killing and immunity genes are known. Our
third aim was to assess how often the S pyocin immunity
gene was responsible for cell resistance to the killing gene.
While it has been observed that some strains appear to not
be killed by S pyocins, despite lacking the immunity gene for
that pyocin, the relative occurrence and importance of this in
nature remains unknown [24].
2. Material and methods
We obtained three collections of lung isolates from the Department
of Clinical Microbiology, Rigshospitalet, Copenhagen, where they
had been isolated from CF patients treated at the Copenhagen CF
clinic (collections 1, 2 and 3 below).
(a) Pseudomonas aeruginosa isolates
Collection 1 consisted of 41 isolates, which we grouped into cat-
egories according to their source of origin: non-lung, or from
infected lungs and the stage of lung infection. Specifically, we
divided these isolates into non-lung strains from the natural
environment or from patient burn wounds (laboratory PAO1),
acute isolates that cause a single intermittent colonization in a
child, chronic isolates that cause a single one-off chronic infection
for less than six months in an adult, and multiply chronic isolates
that are highly transmissible and cause multiple chronic infections
for longer than six months in adults (electronic supplementary
material, table A1). We sequenced all isolates (see the electronic
supplementarymaterial) andbased on the bacterial genomemulti-
locus sequence typing (MLST) profiles the 41 isolates belong to
29 distinct independent genotypes. We used collection 1 to deter-
mine whether the ability to produce, inhibit and resist pyocins,
measured both phenotypically and genotypically, correlates with
how long a strain has been in the lung.
Collection 2 consisted of the genome sequences of 55P. aeruginosa
clinical CF lung isolates [20]. The 55 isolates were of the same geno-
type and belonged to the DK2 clone type, a transmissible Danish
lineage of P. aeruginosa and were sampled from 21 Danish patients
with multiply chronic CF infections over 38 years between 1972 and
2008 (electronic supplementary material, table A2; [20]). We used
these genome sequences to screen for the bacteriocin genes and
analysewhether they are lost or mutated over time during infections.
Collection 3 consisted of longitudinal isolates that had been
sampled from the onset of infection and over 6–10 years from
eight different patients, three of which suffer from chronic infec-
tions and five from acute infections as defined by Marvig et al.
[18] (electronic supplementary material, table A3). The isolates
had already been sequenced at the Department of Clinical Micro-
biology, Rigshospitalet, Copenhagen [18]. Altogether there were
122 isolates that, based on genome MLST profiles, belonged to
17 different genotypes. We used this collection to track changes
in bacteriocin production over time in isolates of the same geno-
type and to track competitive dynamics of co-infecting
genotypes within the same lung environment.
Collection 4 consisted of P. aeruginosa isolates, which had
been previously sequenced and we found in GenBank. These
isolates include CF lung isolates (the Liverpool strain LESB58,
an isolate from a chronically infected patient in Boston
PA2192, the Manchester epidemic strain C3719 and PACS2;
accession numbers: NC_011770, NZ_CH482384, NZ_CH482383,
NZ_AAQW01000001, respectively) and non-lung isolates (PA14:
from a burn wound patient and PA7: a human clinical non-respir-
atory isolate from Argentina; accession numbers: NC_008463 and
NC_009656, respectively). We used these genome sequences to
compare the pyocin gene profiles of other epidemic strains to the
Danish strains and non-lung strains of our collection.
(b) Materials
For all the experiments we used King’s broth (KB) media and agar
to culture bacteria (20 g peptone, 1.5 g K2HPO4.3H2O and 1.5 g
MgSO4.7H2O for the media and an additional 12 g agar powder
for KB agar, per litre of distilled water (dH2O)). We used M9
minimal salts solution to dilute cell cultures (6.8 g Na2HPO4, 3 g
KH2PO4, 0.5 g NaCl and 10 g NH4Cl per litre of dH2O). We used
the Magellan plate reader v. 7.0 and the fluorimeter SpectraMax
M2,Molecular Devices, to take endpointOD reads for constructing
optical density growth curves. The camera box (Syngene Ltd, UK)
G:box EF2 was used for all pictures of bacterial agar plates.
(c) Experimental protocols
(i) Bacterial growth curves
We grew each isolate for 24 h at 378C at 200 r.p.m. in 6 ml of KB
media inoculated from a frozen stock in 20 ml glass vials. We
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measured optical density (OD) at 600 nm (A600), and standar-
dized all cultures to an OD of 1.0 using M9 solution to dilute.
We used 1 ml of standardized culture to inoculate 200 ml of KB
media in a 96-well plate. To construct growth curves we set
the plate to incubate at 378C for 44 h with automatic periodic
shaking every half hour for 15 s prior to OD measurements total-
ling 89 OD reads. We then plotted the growth curves to
determine when each isolate reached stationary phase.
(d) Phenotypic characterization of pyocin production/
resistance
(i) Preparation of supernatant
We cultured all isolates for 24 h at 378C at 200 r.p.m. in 6 ml of
KB media inoculated from a frozen stock in 20 ml glass vials.
We measured cell density at A600 and standardized all cultures
to an OD of 1.0. We then inoculated 30 ml of each standardized
culture into 6 ml of fresh KB media in 20 ml glass vials and
allowed them to grow at 378C at 200 r.p.m. until they reach
stationary phase. We then centrifuged the cultures for 10 min
at 5000g to obtain a clear supernatant, which we filter sterilized
(0.2 mm pore size) into sterile tubes and placed in the freezer at
2208C. We spotted a control KB agar plate with 20 ml of each cul-
ture’s supernatant and incubated them overnight to ensure they
were free of bacterial growth. Although inhibition of strains by
supernatants could be because of small peptides secreted into
the supernatant, the broad killing zones that we observe
will primarily be because of pyocins. We also excluded
inhibition potentially caused by phage lysis (see the electronic
supplementary material).
(ii) Preparation of bacterial lawns
We cultured isolates for 20 or 30 h (for slower growing strains) at
378C at 200 r.p.m. in 6 ml of KB media inoculated from a frozen
stock in 20 ml glass vials. We standardized cultures to OD of 1.0,
and diluted them 100-fold. We then spread 50 ml of each diluted
culture on the supernatant-spotted KB plates.
(iii) Experimental design—using the agar spot assay
We measured the ability of different strains to inhibit each other
by testing whether a strain’s pyocin-carrying supernatant inhibits
a bacterial culture of another strain. We spotted KB agar plates
with the supernatants, and then spread a lawn of each culture
(electronic supplementary material, figure A1). We placed a
20 ml spot of each supernatant onto KB agar plates. We allowed
the spots to dry into the agar before spreading a lawn of 50 ml of
each diluted culture. We then set the plates to incubate at 378C for
12 h until a uniform lawn had appeared. We replicated the same
lawnwith each set of spots three times. Each plate consisted of con-
trol sterile KB media spots and a spot of self-supernatant for each
isolate’s lawn.
We used semiquantitative assays to examine the lawns
for zones of inhibition, or reduced growth on all supernatant
spots for collections 1 and 3. We took pictures of the plates
using a camera with contrasting colour images in order to
better visualize and detect reduced growth when the inhibition
areas were not clear zones (electronic supplementary material,
figure A1). As a control, we confirmed that sterile KB media
and self-supernatant spots did not cause any inhibition of the
lawns. We then recorded which strains inhibited each other
and compiled a 41  41 matrix organized into four isolate cat-
egories of non-lung and three different stages of a CF infection
(acute, chronic one-off and multiply chronic) across the patients.
We also compiled a separate matrix for within-patient isolate
interactions for the eight different patients of collection 3.
(e) Data analysis
(i) Genome sequence analysis—screening for pyocin genes
All isolate genome sequences were assembled de novo using the
assembly software Velvet, the contigs from which were uploaded
to a database running the BIGSdb platform [25]. We assessed the
diversity of isolates using multilocus sequence typing (MLST)
where the genomes were screened for alleles of the seven key
housekeeping loci, acs, aro,mut, nuo, pps, trp and gua, ofP. aeruginosa
available at the www.pubmlst.org/paeruginosa website. The
MLST concept is extended to the whole genome scale screening
for allele variants of a diversity of other loci and we analysed this
data using a genome comparator tool to identify distinct genotypes
among the isolates [25]. For further data analysis, we grouped
isolates with identical genome MLST profiles together as one
independent sample to minimize pseudoreplication.
The BIGSdb software includes ‘autogagger’ and ‘autodefiner’
tools that scan deposited whole genome sequences against loci
identifying exact matches or allele variants with 98% sequence
identity for which new alleles are generated. Isolates’ records
are updated with specified allele numbers marking the regions
on assembled contiguous sequences (contigs) for defined loci.
We blasted the genomes for pyocin genes and tagged the resulting
allelic variants before proceeding with further analysis.
We screened all isolate genomes for the soluble S pyocin (S1,
S2, S3, S4, S5 and AP41) loci and their allele variants for the kill-
ing and corresponding immunity gene using a known sequence
as a reference available from previously sequenced genomes in
NCBI GenBank (electronic supplementary material, table A4).
We also screened the genomes for regulatory (prtN and prtR)
and lysis genes (hol and lys) as well as the R and F pyocin
structural genes (electronic supplementary material, table A4,
figure A2). We used pyocin loci R2 and F2 as reference genes
to screen for other potential alleles that belong to other R and
F pyocin subtypes. The R pyocin is characterized by the presence
of the whole suite of genes between the hol-lys and the F pyocin
by the presence of the toxin loci between lys and trpG (electronic
supplementary material, figure A2). We tagged the genomes of
all isolates and annotated each of the loci and its identified alleles
(electronic supplementary material, figure A3).
For some of the F2 toxin loci, alleles could not be identified
because of high sequence dissimilarity. In such cases, we checked
for the presence of open reading frames (ORF) in the expected
location of the F-specific region and, if present, we marked
them as present but with an unidentified allele. In all isolates
the genes for R and F pyocins are found between trpE and
trpG in one region lying on one contig, facilitating the search
for ORFs in the missing R or F regions.
For our analysis a genewas considered to be present in the iso-
latewhen it is present in its fully functional coding sequence.When
a sequence is truncated and partly found in the genome because it
lies at the edge of a contig it is impossible to determine whether
it exists in the genome as a fully functional coding sequence or a
mutated non-functional gene. We considered genes lying at the
edge of a contig as present and functional for further analysis.
Sequences with premature stop codon mutations are considered
non-functional. If one of the genes in the cassette composing the
R- or F-pyocins is missing in an isolate we consider the pyocin to
be non-functional and as absent. However, this was never the
case, they were either all present together or none at all.
To ensure that the R- and F-pyocin loci are in fact absent from
the genomes and the results are not due to a sequencing error, we
checked whether any other DNA sequence lies in the R- and
F-specific region of the genome. The R-pyocin genes are in a lysis
cassette, between the holin and lys genes, and the F-specific
region is between lys and trpG genes.We found that for all isolates
not caryring R and F pyocins, there are no ORFs between the
holin-lys and lys-trpG loci respectively, confirming the absence
of R- and F-pyocin genes from the isolates.
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(ii) Statistical analysis of phenotypic inhibition profiles
For the 41 isolates taken fromdifferent stages of infection (collection
1), we merged and averaged the data of all isolates with identi-
cal MLST genotypic profiles in each isolate category resulting in a
total of 29 independent samples. To avoid pseudoreplication, we
estimated the number of times isolates of identical genotypes are
inhibited or inhibiting and used the averaged value for the analysis
(electronic supplementary material, figure A4). We tested for
significant differences in inhibition with time spent in the lung
(as estimated by type of CF lung infection) using a generalized
linear model (GLM) with level of inhibition as a response variable
and two explanatory variables: time spent in the lung and type of
P. aeruginosa isolate category. We tested for changes in the pro-
portion of inhibition caused by the isolate’s supernatant as a
function of time isolates spent in the lung and the proportion of
lawns inhibited by supernatants as a function of time bacterial
lawn isolates spent in the lung. We also specifically tested for:
(i) differences in the level of inhibition caused by isolates’ super-
natants of each category on the isolate lawns within each category
and (ii) differences in the level of inhibition in the isolate lawns of
each category caused by the isolates’ supernatants of each category.
For the longitudinal samples from the eight CF patients (col-
lection 3), we did not merge isolates of the same genotype as one
independent sample because the aim of these experiments is to
test for significant differences in inhibition with time of infection
across isolates infecting the same lung. We used GLM analysis to
test for significant differences in inhibition levels with time (in
years) each isolate has spent infecting the lung. In the analysis
we modelled the proportion of killing caused by isolates’ super-
natant as a response variable with time of infection as a
continuous variable and genotype as a discrete variable. This
analysis was done on isolates per patient and isolates across all
patients for more general patterns. The data from both isolate col-
lections are proportion data and so we normalized for residuals
prior to analysis using an arcsine square-root transformation.
(iii) Analysis of S pyocins
To assess the frequency in which producer, resistant and sensi-
tive S pyocin isolates occur we used the genetic data to assess
how often an S pyocin occurred with both its killing and immu-
nity gene, and how often either gene was found alone across all
independent genotypes. When the isolates that share the same
genome MLST type showed variation in their S pyocin profile,
we considered the isolates as independent samples. This resul-
ted in a total of 53 independent samples, with a total of 80
occurrences of S pyocin genes found across all.
To assess whether the S immunity gene is responsible for cell
protection from S pyocins we used the pyocin gene profiles in all
isolates to predict how often one cell carrying the S pyocin will
kill a cell that does not carry that S pyocin (electronic supplemen-
tary material, figure A5). Then we determine how often killing is
observed from the phenotypic experimental data. We then record
how often resistance of the target cell occurs in the presence of
the immunity gene. When the same genotype showed variation
in its S pyocin profile, we also considered the isolates as indepen-
dent samples here. We recorded resistance or susceptibility from
the experimental competitive interactions when more than 50%
of the isolates of each independent genotype are susceptible or
resistant. If exactly 50% of the isolates of a genotype show resist-
ance and the other 50% susceptibility, we record that as data that
cannot be interpreted. This occurred in 25 of 635 competitive
interactions that were therefore excluded from further analysis.
In the majority of cases, there was no discrepancy among isolates
within a genotype, and so the criteria we use above do not
significantly change the results when not applied.
For the above analyses we analysed data of S1, S2, S3, S5 and
AP41 pyocins, but we excluded the S4 pyocin because it is still
unknown whether there is an immunity gene for it, and if
there is, it has not been identified or annotated yet. We used pro-
portion x2-squared to test for significant differences in the
frequency of genes occurring together or alone and to test for sig-
nificant differences in the frequency of strains that resist via
alternative resistance mechanisms and strains that resist using
the immunity gene. We implemented all analyses in R statistical
software (http://www.R-project.org).
3. Results
(a) Pyocin production and resistance
(i) Comparison across patients sampled at different stages
of infection
Considering the 41 isolates taken from different stages of infec-
tions (collection 1), we found that strains that were isolated
from later stage infections were both significantly less likely to
inhibit and more likely to be inhibited by other strains
(figure 1; electronic supplementary material, figure A4; inhibit-
ing: F7,108¼ 10.63, p¼ 4.03  10210; inhibited: F7,108 ¼ 11.14,
p ¼ 1.53  10210; N¼ 29 distinct genotypes). The interaction
terms between the type of lawn inhibited, and the type of
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Figure 1. Proportion of supernatants inhibiting and lawns inhibited. Strains that were isolated from later-stage infections were both (a) less likely to inhibit and
(b) more likely to be inhibited by other strains. The error bars indicate +95% CI bars around mean values.
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supernatant causing inhibition were not significant. Therefore,
excluding the effect of interaction, there is a significant decrease
in the supernatants inhibiting (F4,111¼ 16.91, p ¼ 7.43  10211)
and a significant increase in the lawns being inhibited (F4,111¼
18.9, p ¼ 7.10  10212)with increasing infection time in the lung.
We found that strains had a significantly lower diversity of
pyocins as infections progress to chronic stages (figure 2; GLM,
F1,27¼ 5.003, p ¼ 0.034). Lower pyocin diversity in multiply
chronic transmissible strains can be either because of gene
loss over infection time within a lineage, or that strain lineage
never having had them in the genomes. To determine whether
the pyocin genes are lost from the genomes when a strain
infects for long periods we examined the 55 isolates taken
over 38 years from one of the Danish multiply chronic trans-
missible genotypes (DK2; collection 2). These isolates do not
show loss of or mutation accumulation in the pyocin genes
over time. These data indicate that pyocin genes of transmissi-
ble isolates are not lost with increasing infection time but were
initially never present in the genomes; such that chronic trans-
missible strains are characterized by a lower pyocin diversity
relative to non-chronic isolates.
To compare our results to previously published strains, par-
ticularly that Danish multiply chronic strains carry a reduced
diversity of pyocins, we analysed the genomic pyocin data on
six P. aeruginosa isolates from GenBank, four chronic or epi-
demic CF strains from the UK, Boston and an unknown
source, and two clinical non-lung isolates (collection 3). We
found the same pattern in these isolates that we had found in
our Danish isolates. Similar to the multiply chronic isolates of
our collection, the CF isolates (except for the Liverpool strain)
also show absence of all the R pyocin genes but retain the F
genes, while the clinical non-lung isolates carry both the R
and F pyocin genes, similar to the non-lung isolate category
of our collection (electronic supplementarymaterial, figure A3).
(ii) Comparison over time within patients
We then analysed longitudinal isolates, taken over a 6–10
year period, from eight patients. We found that, within
patients, isolates’ inhibition levels did not change over time
infected (T7 ¼ 20.70, p ¼ 0.505, N ¼ 8)—inhibition increased
in two patients, decreased in four, and there was no inhibition
in two patients. Examining the genomic data of isolates in
patients with multiple infecting genotypes, pyocin diversity
does not vary significantly with the likelihood of persisting
in the lung (T7.73 ¼ 20.43, p ¼ 0.676, N ¼ 5).
Considering the eight patients, five had two or more geno-
types infecting the lung. In two of these patients there was no
inhibition between genotypes. In the remaining three patients,
at least one of the genotypes was able to inhibit the growth of
another genotype in that patient. In two out of these three
patients, the inhibiting genotype persisted longer in the
infection, consistent with a role of bacteriocin-mediated
competition (figure 3). In contrast, in the third patient, the
inhibited genotype persisted longer in the infection.
(b) Linkage between S pyocin killing and immunity
We then examined the extent to which killing and immunity
co-occurred for the five S-type pyocins. We focused on S-type
pyocins because they are composed of two genes, one respon-
sible for the killing activity and an immunity gene that
protects against the killing. Natural populations have been
observed to contain strains that carry both, the toxin and
immunity genes (toxin producers), just the immunity gene
(resistant) or neither (sensitive).
Overall, 98% (53/54) of all independent isolates in all collec-
tions contained at least one S-pyocin gene. The average number
of pyocin types per isolate was 1.5, giving 80 (53  1.5) occur-
rences of pyocin genes. Amongst those, 51% (41/80)
contained both the toxin and the immunity genes, 35% (28/
80) only the killing gene and 14% (11/80) only the immunity
gene, (figure 4; x22,80 ¼ 25:46, p ¼ 2.96  1026). The relatively
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Figure 2. Pyocin diversity across different stages of infection. Isolates from
later-stage infections carry fewer pyocin types than isolates from early infec-
tions and non-lung environments. Circles represent isolates and squares
represent the means of number of pyocin types for each isolate category.
The error bars indicate +95% CI bars around mean values.
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Figure 3. Within patient competitive dynamics. Considering the eight
patients where we were able to follow strain dynamics over time, five
were infected by multiple strains. These patients contained 14 distinct geno-
types, and none of the patients were infected with the same genotype. In
only three of these five patients at least one of the strains was able to inhibit
another strain in the infection. Squares represent genotypes that are not
inhibited nor cause any inhibition; triangles are genotypes that inhibit the
susceptible circle genotypes. In two out of these three patients (P36F2
and P96F4), the inhibiting genotype (triangle) persisted longer in the infec-
tion, consistent with a role of bacteriocin-mediated competition. In the other
patient (P41M3), the inhibited genotype (circle) persisted longer in the
infection, contrary to the prediction from bacteriocin dynamics.
rspb.royalsocietypublishing.org
Proc.R.Soc.B
282:20150972
5
 on October 21, 2015http://rspb.royalsocietypublishing.org/Downloaded from 
high occurrence of only the killing gene occurs only in the
nuclease S pyocins (S1, S2, S3 and AP41). This is surprising,
because this would lead to the isolate killing itself, however,
this is not phenotypically observed for any of the strains tested
in the inhibition assays. Whereas the S5 pyocin, the only
known pore-forming S toxin, which is therefore not lethal
when expressed, occurs a total of 13 times across genotypes but
is always present with the killing and immunity gene together.
We examined the extent to which strains might have
resistance mechanisms other than the specific immunity
genes (electronic supplementary material, figure A5). We
considered 877 strain interactions (competitions), including
the isolates from the different stages of infection and the
longitudinal isolates from the eight patients (collections 1
and 3). Examining our genetic data, we found that in 635 of
these competitions, one strain carried at least one S-type
pyocin that the other strain did not. In 33% (207/635) of
these cases, we found that the toxin carrying strain was
able to inhibit the growth of the other strain. In the 403 inter-
actions where growth was not inhibited, we found that in
19% (77/403) of cases the strain not inhibited contained the
immunity gene to the pyocin(s) being produced by the killing
strain. In the remaining 326 cases (81%, 326/403), the strain
did not have the immunity gene(s) and so must be using
some alternative mechanism to resist the pyocin. Alternative
resistance mechanisms protect strains significantly more fre-
quently than the immunity gene (figure 5; x21,403 ¼ 305:23,
p, 2.2  10216).
4. Discussion
We found that, in P. aeruginosa infections of the CF lung:
(i) isolates from later infection stages caused less inhibition of
other strains, were significantly more inhibited by the pyocins
produced by other strains (figure 1) and carried a significantly
lower diversity of pyocin types (figure 2); (ii) pyocin genes
were not lost from a chronic transmissible strain over time;
(iii) within infections, over time, there is no change in
inhibition/inhibiting levels or pyocin diversity; (iv) pyocin
inhibition profiles do not significantly explain which strains
persist longer within lung infections (figure 3); (v) 35% of S
pyocins occurred only as the killing gene, without the
immunity gene to that pyocin (figure 4); (vi) in cases where
one strain does not carry an S pyocin type carried by another,
resistance via other mechanisms is much more common (81%)
than resistance via the immunity gene (19%; figure 5).
(a) Bacteriocins and strain dominance
We found no support for the hypothesis that certain strains are
able to achieve dominance in the CF lung through bacteriocins
(figures 1 and 3). In fact, we found the opposite pattern, that
more dominant/persistent strains, taken from later infection
stages are less able to kill andmore easily killed by other strains
(figure 1). Our genetic analysis suggests that this pattern arises
because isolates from later infections carry fewer pyocin
genes (figure 2). This pattern could occur through strains
losing pyocin genes overtime, or through strain competition,
with more competitive strains producing less pyocins [26–30].
Our results suggest the latter with more competitive strains
producing fewer pyocins (figure 2) rather than pyocin genes
being lost from strains during infection.
Why do more dominant strains which cause chronic
infections carry a lower diversity of pyocins (figure 2; [29])?
A number of possible selective forces, which are not mutually
exclusive, may be involved. Higher strain diversity, both
within and across species, may favour a higher pyocin diver-
sity required for competition during early stages of infection
[19,31–37]. Another possibility is that higher pyocin diversity
may be more costly in chronic infections if it leads to a higher
antibiotic susceptibility—for example, expression of the R/F
region increases strain susceptibility to fluoroquinolone anti-
biotics due to induction of the lysis system [38]. However,
this does not explain maintenance of the F pyocin in the mul-
tiply chronic isolates of our collection, unless carrying either
R or F rather than both, also makes the cell less inducible and
therefore more resistant to antibiotics.
Within patient infections, strains show no competitive
dominance as a result of bacteriocins and this is because
any given cell is interacting more often with clonemates
that share the same genotype. In which case the bacteriocins
are useless. However, even when interacting with strains of
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different genotypes that are co-infecting, bacteriocins do not
always explain strain persistence and dominance (figure 3).
More often it is the strains that do no inhibit nor are inhibited
by others that persist longest, implying that toxins are not
useful in the CF lung environment. Despite this, strains
retain a diversity of toxins, most probably as a result of adap-
tation to a range of environments they previously colonized.
It is important to note that it is possible that pyocin pro-
duction can vary with the conditions in the CF lung that
would show inhibition profiles different from our exper-
iments. For example, stress-inducing conditions, such as
anaerobic or oxidative stress, usually associated with patho-
genesis in the lung, as well as mutagenic agents inducing
production of all pyocin types but repressing expression of
the S immunity [37–40]. It has also been speculated that
the CF lung is an iron-limited environment [41], which can
make cells more susceptible to S pyocin killing due to upre-
gulated expression of ferri-pyoverdine and pyochelin
receptors, which are required for iron uptake but also serve
as receptors for S pyocins [2,42,43]. However, we note that
our genetic analysis supports the general trends observed in
the phenotype inhibition assays.
(b) Killing and immunity genes
We found that 35% of S pyocins are found as the killing gene
without the corresponding immunity gene (figure 4). This is
surprising because these are nuclease toxins, which suggests
that these strains would kill themselves when expressed.
However, we also found that strain resistance often occurs
without the presence of the immunity gene, suggesting that
whether or not you produce the specified immunity gene in
P. aeruginosa is irrelevant. Considering cases where one strain
does not carry a pyocin type carried by another, resistance
via some other mechanism is much more common (81%)
than resistance via the immunity gene (19%; figure 5). Possible
alternative resistance mechanisms could be production of
another ‘orphan’ immunity protein—as found in other pseu-
domonad species [44], that a secondary receptor is needed in
addition to the primary receptor to allow entry of the pyocin
into the cell or cells have mutations in or are lacking the
primary S pyocin receptors [24,42,43].
We did not find evidence for bacteriocin-mediated compe-
tition explaining strain dynamics and/or producing RPS
dynamics. Such dynamics are still expected even when there
are multiple bacteriocin types in a population [21]. One poss-
ible explanation is that P. aeruginosa bacteriocins do not
appear to involve single production/immunity genes, as we
have shown immunity can occur via alternative mechanisms.
This contrasts with E. coli where bacteriocins are neutralized
by the immunity proteins [45]. Our results suggest that the out-
come of strain competition is being driven primarily by other
factors, which influence the ability to survive and grow in
the CF lung. These could include susceptibility to antibiotics
or attack from the immune system. Another explanation is
that bacteriocinsmay be useless in the CF environment because
they may not penetrate through the mucus layers and reach
target cells, therefore, selecting against high-producing
bacteriocin strains.
To conclude, we have found no evidence that killing by
bacteriocins allows strains to outcompete other strains in
the CF lung. Instead, we found the opposite result that mul-
tiply chronic Danish strains, which are better at surviving and
persisting, as well as other epidemic CF strains carry fewer
bactericions. Screening of bacteriocin profiles may therefore
offer a method for predicting which infections are more
likely to persist as chronic. A major task is to determine
why lower bacteriocin diversity is correlated with the ability
to persist in infections of the CF lung.
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